The company had a pre-investigational new drug (IND) meeting with the FDA last month.
Showing 25 of 1818
The first patient was dosed in the Eastern European country of Moldova.
CE marking is a certification mark that indicates conformity with European health, safety, and environmental protection standards.
This is a niche space that is growing fast and CannPal already has an advantage through its research and product development programs which are well underway.
The AACR annual meeting will be held in Atlanta Georgia, between March 29 and April 3.
New sales teams and product expansion led the continued growth in ADAPT sales in all regions for the period ending December 31, 2018.
This additional finance reinforces the directors’ ongoing commitment and confidence in the company.
The company has multiple B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies.
Imugene is an Australian biotechnology company developing cancer immunotherapies, with operations in the U.S. and in Europe.
Boehringer Ingelheim has completed enrolment of the Phase 2a clinical trial of a Pharmaxis developed drug in NASH.
The clinical trial will include two stages and outcomes will be released in June 2019.
The company has entered the 2019 calendar year in a strong position with a focus on pursuing sales channels that are most profitable, such as Japan.
The TAVR heart valve device utilises the company’s ADAPT® technology.
MPS or mucopolysaccharidoses is an orphan indication with market exclusivity and high profit margins.
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.
Recently published study findings show Cellmid’s midkine antibodies prevented heart muscle damage and preserved function.
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
Leo Lee has extensive experience in leading pharmaceutical companies in Japan having been the former president of Japan for both Merck and Allergan.
The company continued its sales growth trajectory while substantially reducing its debt.
Funds will support the company’s plans to develop its ADAPT portfolio and position itself to develop new products in 2019.
The results of the toxicity studies complete Pharmaxis’ scientific package of data for the LOXL2 program.
The company sells clinically validated anti-ageing products for hair, skin and body.
The partially underwritten issue closed earlier this month and raised $18.96 million.
Bronchitol works by rehydrating the airway/lung surface and promoting a productive cough. It is used for the treatment of cystic fibrosis patients.